PubMed · 42736066
Fusion-product control in hematologic cancers.
Abstract
Oncogenic fusions both drive hematologic cancers and enable precise measurable residual disease tracking, yet whether residual fusion products can be therapeutically controlled remains incompletely defined. Emerging genomic, RNA, and proteostasis strategies now frame fusion control as a layer-matched therapeutic strategy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Min Zhang, Li Yu. 2026-09-14. Fusion-product control in hematologic cancers.. https://doi.org/10.1016/j.trecan.2026.08.008
Cite the original work for its findings. Save a collection to share your selection of sources.